Topics

Articles

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials. 

Evergreen Theragnostics Raises $26M in Capital to Aid Commercialization Efforts for the Ga-68 DOTATOC Diagnostic Kit

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics. 

Does Biosimilar Competition Result in Lower Out-of-Pocket Costs for Patients?

Analysis determines the suggested value of medications for diabetes if they were closer to production costs. 

Predicting Cost-Based Value for Diabetes Medications

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

Who Moved My Prescription? Part III

Podcasts

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency. 

A Further Examination of Pharmacy Benefit Managers

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications. 

Does the Passing of a No Behavioral Health-Cost Sharing Law Have Any Bearing on Spending?

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

Lonza Purchases Roche Biologics Manufacturing Site in California for $1.2 Billion

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

Access USA 2024: The State of the Industry

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

Cancer’s Financial Burden Being Felt Worldwide

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.  

Business and Finance